Astra Therapeutics
Astra Therapeutics develops precision drugs to target eukaryotic pathogens causing human, animal, and plant diseases.
About
Astra Therapeutics is dedicated to discovering and developing innovative therapies to treat serious diseases caused by eukaryotic pathogens. Using atomic resolution comparative structural data, the company engineers pathogen-specific cytotoxic agents to combat infections in humans, animals, and plants. Astra Therapeutics focuses on targeting the molecular infrastructure of eukaryotic pathogens, particularly their unique microtubule cytoskeleton, to develop safe and potent drugs. Their ParaX platform enables precision drug engineering to create species-specific parasite inhibitors called Parabulins. The founding team consists of experienced scientists and business development leaders in animal health and agriculture.
Products & Services
- ParaX Platform (Precision Lead Generator)
- Parabulins (Precision-engineered drugs against specific eukaryotic pathogens)
- Drug Development for Pathogenic Protozoa
- Drug Development for Roundworms & Flatworms (Helminths)
Use Cases & Case Studies
-
Partnerships & Collaborations
- Paul Scherrer Institute (research and prior employment of founders)
- Industrial partners and technology developers (mentioned as prior experience of founders)
Awards & Recognition
- Novartis FreeNovation Grant (2017)
- Swiss National Science Foundation Spark Grant (2019)
- Venture Kick Support
- Innosuisse Initial Coaching